ClinicalTrialsFinder

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) Clinical Trials in Changsha, Hunan

1 recruitingChangsha, Hunan, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
Hunan Province Tumor Hospital156 enrolled2 locationsNCT07251582